Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Other Non-Current Liabilities: 2011-2016

Historic Other Non-Current Liabilities for RedHill Biopharma (RDHL) over the last 4 years, with Dec 2016 value amounting to $1.1 million.

  • RedHill Biopharma's Other Non-Current Liabilities changed negligibly% to $1.1 million in Q4 2016 from the same period last year, while for Dec 2016 it was $1.1 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.1 million for FY2016, which is negligibly% changed negligibly from last year.
  • RedHill Biopharma's Other Non-Current Liabilities amounted to $1.1 million in Q4 2016, which was down 0.00% from $1.1 million recorded in Q3 2016.
  • RedHill Biopharma's Other Non-Current Liabilities' 5-year high stood at $3.3 million during Q4 2012, with a 5-year trough of $1.1 million in Q1 2015.
  • Its 3-year average for Other Non-Current Liabilities is $1.2 million, with a median of $1.1 million in 2016.
  • In the last 5 years, RedHill Biopharma's Other Non-Current Liabilities increased by 21.85% in 2012 and then tumbled by 52.72% in 2014.
  • Over the past 5 years, RedHill Biopharma's Other Non-Current Liabilities (Quarterly) stood at $3.3 million in 2012, then crashed by 42.96% to $1.9 million in 2013, then decreased by 18.16% to $1.5 million in 2014, then tumbled by 30.82% to $1.1 million in 2015, then remained steady at $1.1 million in 2016.
  • Its Other Non-Current Liabilities stands at $1.1 million for Q4 2016, versus $1.1 million for Q3 2016 and $1.1 million for Q2 2016.